Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-06-03T02:52:49.263Z Has data issue: false hasContentIssue false
  • English
  • Français

Comorbid HIV Encephalopathy and Cocaine Use as a Risk Factor for New-onset Seizure Disorders

Published online by Cambridge University Press:  07 November 2014

Christopher A. Kenedi ,
Karen E. Joynt  and
Harold W. Goforth
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients living with human immunodeficiency virus represent a growing population, and an increased number of central nervous system presentations can be expected over the next decade. Emerging data suggests that both HIV-seropositive patients and cocaine-abusing patients may be at special risk of seizure phenomena. This case report discusses the risks of new-onset seizure activity when these two risk factors converge, which is a common occurrence in this population. Data from the fields of neuroanatomy and neurovirology are presented to explain the heightened risk of this patient population and provide the practitioner with an improved understanding of the central nervous system complexities in HIV.

Type
Case Report
Information
CNS Spectrums , Volume 13 , Issue 3 , March 2008 , pp. 230 - 234
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Levy, RM, Bredesen, DE, Rosenblum, ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg. 1985;62:475–495.CrossRefGoogle ScholarPubMed
2.Holtzman, DM, Kaku, DA, So, YT. New-onset seizures associated with human immunodeficiency virus infection: causation and clinical features in 100 cases. Am J Med. 1989;87:173–177.CrossRefGoogle ScholarPubMed
3.Goforth, HW, Konopka, L. Electrophysiology of HIV disease. In: Fernandez, F, Ruiz, P, eds. Psychiatric Aspects of HIV-AIDS. Philadelphia, Penn: Lippincott Williams and Wilkins Publishers; 2006:63–71.Google Scholar
4.Berger, JR, Simpson, DM. Neurologie complications of AIDS. In: Scheid, WM, Whitley, RJ, Durack, DT, eds. Infections of the Central Nervous System. Philadelphia, Penn: Lippincott-Raven; 1997:255–271.Google Scholar
5.Pesola, GR, Westfal, RE. New-onset generalized seizures in patients with AIDS presenting to an emergency department. Acad Emerg Med. 1998:5:905–911.CrossRefGoogle ScholarPubMed
6.Miller, RF, Lucas, SB. Hali-Craggs, MA, et al.Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS. J Neurol Neurosurg Psychiatry. 1997;62:346–351.CrossRefGoogle ScholarPubMed
7.Meitzer, C, Wells, S, Becher, M, Flanigan, K, Oyler, G, Lee, R. AIDS-related MR hyper-intensity of the basal ganglia. Am J Neuroradiol. 1998;19:83–89.Google Scholar
8.Nath, A, Maragos, WF. Avison, MJ. Schmitt, FA, Berger, JR. Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol. 2001;7:66–71.Google ScholarPubMed
9.Bansal, AK, MacTutus, CFNath, A, Maragos, W. Hauser, KF, Booze, RM. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 2001:879:42–49.CrossRefGoogle Scholar
10.Rottenberg, DA, Sidtis, JJ, Strother, SC. et al.Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med. 1996;37:1133–1141.Google ScholarPubMed
11.Chang, L, Ernst, T, Speck, O, Grob, CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005;162:361–369.CrossRefGoogle ScholarPubMed
12.Wang, G-J. Chang, L, Volkow, N, et al.Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain. 2004;127(pt 11):2452–2458.CrossRefGoogle ScholarPubMed
13.Maragos, WFYoung, KL, Turchan, JTet al.Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem. 2002; 83: 955–963.CrossRefGoogle ScholarPubMed
14.Han, DD, Gu, HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6:6.CrossRefGoogle ScholarPubMed
15.Witkin, JM, Gasior, M. Dopamine D3 receptor involvement in the convulsant and lethal effects of cocaine. Pol J Pharmacol. 1998;50(suppl):44–45.Google Scholar